{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:15:55Z","timestamp":1792624555152,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jfma.2021.06.012","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T02:52:44Z","timestamp":1626317564000},"page":"2061-2071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Management of neovascular age-related macular degeneration: Taiwan expert consensus"],"prefix":"10.1016","volume":"120","author":[{"given":"Ling","family":"Yeung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ting","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9798-1578","authenticated-orcid":false,"given":"Shih-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Kuo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwu-Jiuan","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yao","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Tien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-381X","authenticated-orcid":false,"given":"San-Ni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jfma.2021.06.012_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0161-6420(00)00580-7","article-title":"Risk factors for age-related macular degeneration: pooled findings from three continents","volume":"108","author":"Smith","year":"2001","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.jfma.2021.06.012_bib2","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"5","key":"10.1016\/j.jfma.2021.06.012_bib3","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.ophtha.2009.10.007","article-title":"The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis","volume":"117","author":"Kawasaki","year":"2010","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.jfma.2021.06.012_bib4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/ceo.13580","article-title":"Prevalence of age-related macular degeneration in Chinese populations worldwide: a systematic review and meta-analysis","volume":"47","author":"Jin","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.jfma.2021.06.012_bib5","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1167\/iovs.08-1803","article-title":"Prevalence and associated risk factors of age-related macular degeneration in an elderly Chinese population in Taiwan: the Shihpai Eye Study","volume":"49","author":"Chen","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.jfma.2021.06.012_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/eye.2014.55","article-title":"Prevalence and risk factors for age-related macular degeneration in the elderly Chinese population in south-western Taiwan: the Puzih eye study","volume":"28","author":"Huang","year":"2014","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.jfma.2021.06.012_bib7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s10384-012-0178-8","article-title":"Prevalence and causes of visual impairment in elderly Amis aborigines in eastern Taiwan (the Amis eye study)","volume":"56","author":"Chen","year":"2012","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"10.1016\/j.jfma.2021.06.012_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00055735-200206000-00007","article-title":"Risk factors for age-related macular degeneration: an update","volume":"13","author":"Hyman","year":"2002","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jfma.2021.06.012_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.preteyeres.2016.04.003","article-title":"Risk factors and biomarkers of age-related macular degeneration","volume":"54","author":"Lambert","year":"2016","journal-title":"Prog Retin Eye Res"},{"issue":"14","key":"10.1016\/j.jfma.2021.06.012_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jama.1996.03540140035023","article-title":"A prospective study of cigarette smoking and risk of age-related macular degeneration in men","volume":"276","author":"Christen","year":"1996","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jfma.2021.06.012_bib11","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0161-6420(94)31139-0","article-title":"Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors","volume":"101","author":"Holz","year":"1994","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1016\/j.jfma.2021.06.012_bib12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jama.1996.03540140029022","article-title":"A prospective study of cigarette smoking and age-related macular degeneration in women","volume":"276","author":"Seddon","year":"1996","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jfma.2021.06.012_bib13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/archopht.118.2.264","article-title":"Age-specific causes of bilateral visual impairment","volume":"118","author":"Weih","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.jfma.2021.06.012_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120003","article-title":"Association between neovascular age-related macular degeneration and dementia: a population-based case-control study in Taiwan","volume":"10","author":"Chung","year":"2015","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.jfma.2021.06.012_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jfma.2019.04.012","article-title":"Management of polypoidal choroidal vasculopathy: experts consensus in Taiwan","volume":"119","author":"Chen","year":"2020","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"10.1016\/j.jfma.2021.06.012_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/IAE.0000000000001556","article-title":"Angiographic SUBTYPES OF polypoidal choroidal vasculopathy IN Taiwan: a prospective multicenter study","volume":"38","author":"Yeung","year":"2018","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.jfma.2021.06.012_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/tvst.4.3.6","article-title":"Optimizing the anti-VEGF treatment strategy for neovascular age-related macular degeneration: from clinical trials to real-life requirements","volume":"4","author":"Mantel","year":"2015","journal-title":"Transl Vis Sci Technol"},{"issue":"4","key":"10.1016\/j.jfma.2021.06.012_bib18","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ophtha.2015.12.001","article-title":"Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment","volume":"123","author":"Mueller","year":"2016","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.jfma.2021.06.012_bib19","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1007\/s00417-017-3739-1","article-title":"Treatment of age-related neovascular macular degeneration: the patient's perspective","volume":"255","author":"Muller","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfma.2021.06.012_bib20","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.2147\/OPTH.S185052","article-title":"The burden of neovascular age-related macular degeneration: a patient's perspective","volume":"12","author":"Spooner","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.jfma.2021.06.012_bib21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/JCMA.0000000000000138","article-title":"Priority options of anti-vascular endothelial growth factor agents in wet age-related macular degeneration under the National Health Insurance Program","volume":"82","author":"Chou","year":"2019","journal-title":"J Chin Med Assoc"},{"issue":"1","key":"10.1016\/j.jfma.2021.06.012_bib22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41598-018-36704-6","article-title":"Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study","volume":"9","author":"Lai","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2021.06.012_bib23","doi-asserted-by":"crossref","first-page":"4538135","DOI":"10.1155\/2020\/4538135","article-title":"Three-Year outcomes of patients with neovascular age-related macular degeneration treated with aflibercept under the national health insurance program in Taiwan","volume":"2020","author":"Lo","year":"2020","journal-title":"J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jfma.2021.06.012_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4103\/tjo.tjo_34_19","article-title":"Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: a 4-year longitudinal study","volume":"9","author":"Yang","year":"2019","journal-title":"Taiwan J Ophthalmol"},{"issue":"10","key":"10.1016\/j.jfma.2021.06.012_bib25","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8","volume":"119","author":"Age-Related Eye Disease Study Research","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.jfma.2021.06.012_bib26","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfma.2021.06.012_bib27","series-title":"Age-related macular degeneration (NG82)","author":"NICE Guidance","year":"2018"},{"key":"10.1016\/j.jfma.2021.06.012_bib28","series-title":"Preferred practice pattern guidelines","article-title":"Age-related macular degeneration","year":"2019"},{"issue":"7","key":"10.1016\/j.jfma.2021.06.012_bib29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","article-title":"Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials","volume":"123","author":"Waldstein","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.jfma.2021.06.012_bib30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.jfma.2021.06.012_bib31","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1167\/iovs.09-5018","article-title":"Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy","volume":"52","author":"Golbaz","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.jfma.2021.06.012_bib32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","article-title":"Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration","volume":"120","author":"Ying","year":"2013","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.jfma.2021.06.012_bib33","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/IAE.0b013e31817d5d03","article-title":"Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis","volume":"28","author":"Chiang","year":"2008","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.jfma.2021.06.012_bib34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/bjo.69.6.397","article-title":"Retinal pigment epithelial detachments in the elderly: classification and outcome","volume":"69","author":"Casswell","year":"1985","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.jfma.2021.06.012_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186955","article-title":"Advanced quantitative analysis of the sub-retinal pigment epithelial space in recurrent neovascular age-related macular degeneration","volume":"12","author":"Sasaki","year":"2017","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.jfma.2021.06.012_bib36","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","article-title":"Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration","volume":"122","author":"Schmidt-Erfurth","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jfma.2021.06.012_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000354551","article-title":"Relationship between visual acuity and spectral domain optical coherence tomography retinal parameters in neovascular age-related macular degeneration","volume":"231","author":"Ristau","year":"2014","journal-title":"Ophthalmologica"},{"issue":"9","key":"10.1016\/j.jfma.2021.06.012_bib38","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","article-title":"Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials","volume":"122","author":"Willoughby","year":"2015","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.jfma.2021.06.012_bib39","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1097\/IAE.0000000000000207","article-title":"The pearl necklace sign: a novel spectral domain optical coherence tomography finding in exudative macular disease","volume":"34","author":"Gelman","year":"2014","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.jfma.2021.06.012_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00417-019-04546-1","article-title":"Hyperreflective foci in predicting the treatment outcome of antivascular endothelial growth factor in neovascular age-related macular degeneration","volume":"258","author":"Hsia","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.jfma.2021.06.012_bib41","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jfma.2021.06.012_bib42","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","article-title":"Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study","volume":"118","author":"Holz","year":"2011","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.jfma.2021.06.012_bib43","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.jfma.2021.06.012_bib44","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.ophtha.2015.08.014","article-title":"Scheduled versus pro Re nata dosing in the VIEW trials","volume":"122","author":"Richard","year":"2015","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.jfma.2021.06.012_bib45","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00417-011-1636-6","article-title":"Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome","volume":"249","author":"Gerding","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.jfma.2021.06.012_bib46","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","article-title":"Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration","volume":"121","author":"Simader","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.jfma.2021.06.012_bib47","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","article-title":"Association of baseline characteristics and early vision response with 2-year vision outcomes in the comparison of AMD treatments trials (CATT)","volume":"122","author":"Ying","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jfma.2021.06.012_bib48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfma.2021.06.012_bib49","series-title":"Association for research in vision and Ophthalmology 2019 annual meeting","first-page":"3456","article-title":"Associations between variation in retinal thickness and visual function","author":"Rebecca Nicole Evans","year":"2019"},{"issue":"9","key":"10.1016\/j.jfma.2021.06.012_bib50","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"14","key":"10.1016\/j.jfma.2021.06.012_bib51","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jfma.2021.06.012_bib52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1016\/j.jfma.2021.06.012_bib53","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jfma.2021.06.012_bib54","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.jfma.2021.06.012_bib55","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.ophtha.2016.05.016","article-title":"Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid","volume":"123","author":"Jaffe","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jfma.2021.06.012_bib56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1755-3768.2011.02268.x","article-title":"Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment","volume":"91","author":"Bloch","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"10.1016\/j.jfma.2021.06.012_bib57","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/eye.2015.167","article-title":"Understanding the patient's lived experience of neovascular age-related macular degeneration: a qualitative study","volume":"29","author":"McCloud","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jfma.2021.06.012_bib58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/OPTH.S125676","article-title":"Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis","volume":"11","author":"Spooner","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"10.1016\/j.jfma.2021.06.012_bib59","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/bjophthalmol-2019-314251","article-title":"Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study","volume":"104","author":"Gale","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jfma.2021.06.012_bib60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000451065","article-title":"Characteristics and predictors of early and delayed responders to ranibizumab treatment in neovascular age-related macular degeneration: a retrospective analysis from the ANCHOR, MARINA, HARBOR, and CATT trials","volume":"236","author":"Gale","year":"2016","journal-title":"Ophthalmologica"},{"issue":"6","key":"10.1016\/j.jfma.2021.06.012_bib61","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.jfma.2021.06.012_bib62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/IAE.0b013e318263cedf","article-title":"Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration","volume":"33","author":"Brown","year":"2013","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.jfma.2021.06.012_bib63","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR : a randomized controlled trial","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.jfma.2021.06.012_bib64","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41433-019-0747-x","article-title":"Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration","volume":"34","author":"Ross","year":"2020","journal-title":"Eye (Lond)"},{"issue":"20","key":"10.1016\/j.jfma.2021.06.012_bib65","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Group","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jfma.2021.06.012_bib66","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.jfma.2021.06.012_bib67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/IAE.0000000000001923","article-title":"Exit strategy in a treat-and-extend regimen for exudative age-related macular degeneration","volume":"39","author":"Arendt","year":"2019","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.jfma.2021.06.012_bib68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.oret.2017.07.009","article-title":"Recurrence rate of choroidal neovascularization in neovascular age-related macular degeneration managed with a treat-extend-stop protocol","volume":"2","author":"Adrean","year":"2018","journal-title":"Ophthalmol Retina"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621002928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621002928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:45:17Z","timestamp":1760539517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664621002928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0929664621002928"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2021.06.012","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of neovascular age-related macular degeneration: Taiwan expert consensus","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2021.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}